Pantostad 40

Pantoprazole

Treatment of GERD, PUD. Prophylaxis for NSAID-associated ulceration. Treatment of pathological hypersecretory states (Zollinger-Ellison syndrome).

GERD 20-40 mg once daily for 4 wk, increased to 8 wk if necessary. Maintenance therapy: 20-40 mg daily. For recurring symptoms, an on-demand of 20 mg daily may be given. PUD 40 mg once daily. Duration of treatment: 2-4 wk for duodenal ulceration or 4-8 wk for benign gastric ulceration. Eradication of H. pylori Pantoprazole may be combined w/ 2 antibacterials in a 1-wk triple therapy regimen. Effective regimens: Pantoprazole 40 mg bd + clarithromycin 500 mg bd + amoxicillin 1 g bd, or combined w/ clarithromycin 250 mg bd + metronidazole 400 mg bd. Prophylaxis for NSAID-associated ulceration 20 mg daily. Treatment of pathological hypersecretory states (Zollinger-Ellison syndrome) Initially 80 mg daily, adjusted as required. Doses up to 240 mg daily have been used. Daily doses >80 mg should be given in 2 divided doses. Renal impairment Max of 40 mg daily.

May be taken with or without food: Swallow whole, do not chew/crush.

Hypersensitivity to pantoprazole or other substituted benzimidazoles (eg, esomeprazole, lansoprazole, omeprazole, rabeprazole ).

Possibility of malignant GI ulcer should be excluded prior treatment, as pantoprazole may mask the symptoms & thus delay diagnosis. Mild, transient elevations of serum ALT (SGPT). Malabsorption of cyanocobalamin. Slightly increased risk of GI infections eg, Salmonella & Campylobacter & possibly C. difficile. Long-term (a year or longer) & multiple daily dose PPI therapy may be associated w/ an increased risk for osteoporosis-related fractures of the hip, wrist or spine. Patients should not drive or operate machines. Pregnancy & lactation. Childn <18 yr.

Uncommon: Sleep disorders, headache, dizziness, taste disorders, diarrhoea, nausea/vomiting, abdominal distension & bloating, constipation, dry mouth, abdominal pain & discomfort, liver enzymes increased, rash/exanthema/eruption, pruritus, asthenia, fatigue & malaise.

Increased or decreased drug absorption at increased gastric pH values w/ gastric pH-dependent drugs (eg, ampicillin esters, Fe salts, ketoconazole). Potential increased INR & prothrombin time when used concomitantly w/ warfarin. Potential delayed absorption & decreased bioavailability w/ sucralfate. Possibility of methotrexate toxicities.

Antacids, Antireflux Agents & Antiulcerants

A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

P₁S₁S₃